Management of Uterine Sarcomas - Current Concepts and Controversies

Authors

  • Beena K Deparment of Radiation Oncology, Amrita Institute of Medical Sciences, Amrita Vishwa Vidyapeetham, Kochi, Kerala, India
  • Anand RK Deparment of Radiotherapy, Medical College, Trivandrum, Kerala, India

Abstract

Uterine sarcomas are a group of relatively rare malignancies with heterologous clinical behavior. Because of its rarity, there is dearth of randomized trials and hence there are no standard recommendations as how to manage these cases. Carcinosarcomas are now a separate entity and is managed similar to high grade endometrial carcinoma, since the sarcomatous element is proven to be of endometrial origin. Now, the major variants are leomyosarcoma (LMS), endometrial stromalsarcoma (ESS) and high grade undifferentiated uterine sarcoma (HGUS). Recently, immunohistochemistry markers are introduced for proper typing of these tumors. Pre- operative diagnosis is seldom possible and surgery remains the cornerstone of its management. Local radiation is found to be beneficial in adjuvant setting with improved locoregional failure free survival (LRFFS) without a proven benefit in overall survival. Adjuvant chemotherapy also is yet to demonstrate overall survival benefit. Multi-institutional studies through international rare cancer initiative may generate ample evidence for standard treatment guidelines in these rare tumors and hence participation in clinical trials is highly recommended.

Keywords: Uterine sarcomas, ESS, LMS, HGUS, adjuvant, radiation, chemotherapy

Cite this Article

Beena K, Anand RK. Management of Uterine Sarcomas-Current Concepts and Controversies. Research and Reviews: Journal of Oncology and Hematology. 2015; 4(3): 19–26p.


 

Downloads

Additional Files

Published

2015-12-29

Issue

Vol. 4 No. 3 (2015)

Section

Review Articles

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is notpublished already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  • I/We also agree to the authorship of the article in the following order:

Author’s name

 

1. ________________

2. ________________

3. ________________

_______________

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.